Literature DB >> 6386022

Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

D P Nicholls, J McNeill, P C O'Connor, D W Harron, W J Leahey, R G Shanks.   

Abstract

The effects of single oral doses of indoramin (mean dose 58 mg), abetalol (mean dose 150 mg), alinidine 80 mg and placebo on arterial pressure and heart rate in the supine and standing positions were studied in six normal volunteers. Doses were chosen to give equivalent reductions of arterial pressure in the standing position. Observations were made before and at 2 and 4 h after drug administration. Plasma noradrenaline (NA) was measured at each time interval in the supine position, and after 4 min of standing. Plasma renin activity (PRA) was measured at each time interval after 30 min in the standing position. In the supine position, alinidine produced a significant reduction of systolic arterial pressure from 124.0 +/- 3.0 mm Hg to 104.3 +/- 4.1 mm Hg at 2 h (P less than 0.01) and to 101.7 +/- 2.2 mm Hg at 4 h (P less than 0.01). Diastolic pressure was reduced from 74.7 +/- 2.6 mm Hg to 57.0 +/- 4.6 mm Hg at 4 h (P less than 0.01). Arterial pressure was unchanged after indoramin or labetalol administration. In the supine position, heart rate was unchanged after indoramin, and small reductions were observed after labetalol and alinidine. Indoramin produced a significant increase in plasma NA. A small increase of plasma NA was observed after labetalol, and a small decrease after alinidine. In the standing position, the three active drugs reduced systolic arterial pressure to a similar extent (indoramin, -26.7 mm Hg at 4 h after drug administration; labetalol, -21.3 mm Hg at 2 h; alinidine, -21.7 mm Hg at 4 h).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386022      PMCID: PMC1463526          DOI: 10.1111/j.1365-2125.1984.tb02455.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  43 in total

1.  Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man.

Authors:  L M Wing; J L Reid; C A Hamilton; P Sever; D S Davies; C T Dollery
Journal:  Clin Sci Mol Med       Date:  1977-07

2.  Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.

Authors:  D S Davies; A M Wing; J L Reid; D M Neill; P Tippett; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

3.  Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man.

Authors:  C R Lake; M G Ziegler; I J Kopin
Journal:  Life Sci       Date:  1976-06-01       Impact factor: 5.037

4.  A comparison of the cardiovascular actions of indoramin, propranolol, lignocaine, and quinidine.

Authors:  B J Alps; E T Borrows; E S Johnson; M W Staniforth; A B Wilson
Journal:  Cardiovasc Res       Date:  1972-05       Impact factor: 10.787

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man.

Authors:  A J Boakes; E J Knight; B N Prichard
Journal:  Clin Sci       Date:  1971-04       Impact factor: 6.124

7.  The relationship between plasma catecholamine concentration and pulse rate during exercise and standing.

Authors:  N J Christensen; O Brandsborg
Journal:  Eur J Clin Invest       Date:  1973-07       Impact factor: 4.686

8.  Arterial noradrenaline concentration during exercise in relation to the relative work levels.

Authors:  J Häggendal; L H Hartley; B Saltin
Journal:  Scand J Clin Lab Invest       Date:  1970-12       Impact factor: 1.713

9.  Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

Authors:  J Mehta; J N Cohn
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

10.  Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise.

Authors:  D A Richards; E P Woodings; J G Maconochie
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

View more
  2 in total

Review 1.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 2.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.